Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Bayle A, Belcaid L, Aldea M, Vasseur D, Peyraud F, Nicotra C, Geraud A, Sakkal M, Seknazi L, Cerbone L, Blanc-Durand F, Hadoux J, Mosele F, Tagliamento M, Bernard-Tessier A, Verret B, Smolenschi C, Clodion R, Auger N, Romano PM, Gazzah A, Camus MN, Micol J, Caron O, Hollebecque A, Loriot Y, Besse B, Lacroix L, Rouleau E, Ponce S, Soria JC, Barlesi F, Andre F, Italiano A. Bayle A, et al. Among authors: barlesi f. Ann Oncol. 2023 Apr;34(4):389-396. doi: 10.1016/j.annonc.2023.01.008. Epub 2023 Jan 25. Ann Oncol. 2023. PMID: 36709039 Free article.
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea M, Tagliamento M, Bayle A, Vasseur D, Vergé V, Marinello A, Danlos FX, Blanc-Durand F, Bernard E, Cerbone L, Mosele MF, Renneville A, Hadoux J, Loriot Y, Sakkal M, Vozy A, Sarkozy C, Smolenschi C, Nicotra C, Martin-Romano P, Boccon-Gibod C, Habza W, Lazarovici J, Ponce S, Hollebecque A, Marzac C, Lacroix L, Barlesi F, André F, Besse B, Rouleau E, Italiano A, Micol JB. Aldea M, et al. Among authors: barlesi f. JCO Precis Oncol. 2023 Mar;7:e2200583. doi: 10.1200/PO.22.00583. JCO Precis Oncol. 2023. PMID: 36862966
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
Levy A, Khalifa J, Martin E, Botticella A, Quevrin C, Lavaud P, Aldea M, Besse B, Planchard D, Barlesi F, Deutsch E, Massabeau C, Doyen J, Le Péchoux C. Levy A, et al. Among authors: barlesi f. Clin Transl Radiat Oncol. 2023 May 3;41:100637. doi: 10.1016/j.ctro.2023.100637. eCollection 2023 Jul. Clin Transl Radiat Oncol. 2023. PMID: 37206411 Free PMC article.
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, Jerusalem G, Penel N, Saada-Bouzid E, Garrido P, Helwig C, Locke G, Ojalvo LS, Gulley JL. Barlesi F, et al. Oncologist. 2023 Mar 17;28(3):258-267. doi: 10.1093/oncolo/oyac253. Oncologist. 2023. PMID: 36571770 Free PMC article.
Anti-TIGIT therapies for solid tumors: a systematic review.
Rousseau A, Parisi C, Barlesi F. Rousseau A, et al. Among authors: barlesi f. ESMO Open. 2023 Apr;8(2):101184. doi: 10.1016/j.esmoop.2023.101184. Epub 2023 Mar 16. ESMO Open. 2023. PMID: 36933320 Free PMC article. Review.
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Danlos FX, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G, Willekens C, Vasse M, Griscelli F, Fahrner JE, Goubet AG, Dubuisson A, Derosa L, Nirmalathasan N, Bredel D, Mouraud S, Pradon C, Stoclin A, Rozenberg F, Duchemin J, Jourdi G, Ellouze S, Levavasseur F, Albigès L, Soria JC, Barlesi F, Solary E, André F, Pène F, Ackerman F, Mouthon L, Zitvogel L, Marabelle A, Michot JM, Fontenay M, Kroemer G. Danlos FX, et al. Among authors: barlesi f. Cell Death Dis. 2024 Feb 14;15(2):142. doi: 10.1038/s41419-024-06519-7. Cell Death Dis. 2024. PMID: 38355585 Free PMC article. No abstract available.
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.
Charton E, Baldini C, Fayet Y, Schultz E, Auroy L, Vallier E, Italiano A, Robert M, Coquan E, Isambert N, Moreau P, Touzeau C, Le Tourneau C, Ghrieb Z, Kiladjian JJ, Delord JP, Gomez Roca C, Vey N, Barlesi F, Lesimple T, Penel N, Soria JC, Massard C, Besle S. Charton E, et al. Among authors: barlesi f. ESMO Open. 2023 Aug;8(4):101610. doi: 10.1016/j.esmoop.2023.101610. Epub 2023 Aug 1. ESMO Open. 2023. PMID: 37536254 Free PMC article.
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group. Reck M, et al. Among authors: barlesi f. Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25. Lancet Respir Med. 2019. PMID: 30922878 Clinical Trial.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Olivier L, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: barlesi f. Eur J Cancer. 2024 May 4;205:114075. doi: 10.1016/j.ejca.2024.114075. Online ahead of print. Eur J Cancer. 2024. PMID: 38733717 Review.
458 results